R1c mAb treatment did not affect core body temperature, energy expenditure, spontaneous locomotor activity, muscle wasting, general behavior or systemic MCP1 levels arguing against general inflammation-induced cachexia as a mechanism for R1c mAb mediated inhibition of food intake and body weight loss. The gene discussed is CCL2; the disease is Cachexia.